Related references
Note: Only part of the references are listed.25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis
Pilar Peris et al.
BONE (2012)
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis
T. Lin et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long?
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Patients with cirrhosis and ascites have false values of bone density Implications for the diagnosis of osteoporosis
N. Guanabens et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Parenteral Bisphosphonates for Osteoporosis in Patients With Primary Biliary Cirrhosis
Sombat Treeprasertsuk et al.
AMERICAN JOURNAL OF THERAPEUTICS (2011)
Liver and bone
Nuria Guanabens et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis
Nuria Guanabens et al.
GASTROENTEROLOGY (2010)
MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE
A. Pares et al.
JOURNAL OF HEPATOLOGY (2010)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Bone disorders in chronic liver disease
Jane Collier
HEPATOLOGY (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
Pierre D. Delmas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
F. Atamaz et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Adherence, patient preference and dosing frequency: Understanding the relationship
JY Reginster et al.
BONE (2006)
Osteoporosis in primary biliary cirrhosis: A randomized trial of the efficacy and feasibility of estrogen/progestin
Robert H. Boone et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Treatment of bone disorders in liver disease
Albert Pares et al.
JOURNAL OF HEPATOLOGY (2006)
Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial
CO Zein et al.
HEPATOLOGY (2005)
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
JA Cramer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study
C Levy et al.
LIVER INTERNATIONAL (2005)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis
S Ormarsdóttir et al.
JOURNAL OF INTERNAL MEDICINE (2004)
AGA Technical Review on osteoporosis in hepatic disorders
WD Leslie et al.
GASTROENTEROLOGY (2003)
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
KVN Menon et al.
JOURNAL OF HEPATOLOGY (2001)
Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial
KD Lindor et al.
JOURNAL OF HEPATOLOGY (2000)
Share Paper
